The OBBBA Tax Recalibration
13 of 19 filers across 2 sectors are noting regulatory exposure. Visible since 2025Q2, recently cooling. Direction flipped — 2025Q2 was 46% neutral; 2026Q1 now 50% falling. Reached 8 sectors at its 2025Q4 peak, now 2 sectors. Almost entirely a regulatory story (88%). Forward-leaning — companies are guiding to this, not just explaining the past. Recent filings describe "OBBBA includes revisions to international tax regimes, repeal of mandatory capitalization of research and development expenditures, and extension of bonus depreciation."
Companies are reassessing the fiscal and cash-flow impacts of the newly enacted Omnibus Budget Reconciliation Act, which restructures U.S. tax incentives including R&D expensing, bonus depreciation, and FDII treatment, while implementing healthcare spending cuts.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Language shifts from anticipatory regulatory risk to concrete quantification of near-term and multi-year tax-rate and cash-flow effects.
REPRESENTATIVE SIGNAL FROM FILINGS
“OBBBA includes revisions to international tax regimes, repeal of mandatory capitalization of research and development expenditures, and extension of bonus depreciation”
The OBBBA includes revisions to international tax regimes, repeal of mandatory R&D capitalization, and extension of bonus depreciation.
“enactment of the OBBBA which modified tax legislation affecting clean energy tax credits”
OBBBA modifications to tax legislation affect the clean energy tax credits available to NEE.
DRIVERS